SCHEMBL17865259

SCHEMBL17865259

Cn1nccc1C(O)c1ccncc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
CYP17A1 P05093 1/20 0.42
CYP19A1 P11511 1/20 0.42
KDM4E B2RXH2 3/20 0.38
LTA4H P09960 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
CYP2C19 P33261 2/20 0.35
HSD17B10 Q99714 1/20 0.35
BRD4 O60885 1/20 0.35
COMT P21964 1/20 0.34
PRKDC P78527 1/20 0.34
KCNH2 Q12809 1/20 0.34
GAA P10253 1/20 0.33
LATS1 O95835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7590836 0.87 KDM4E (0.50) CYP19A1KDM4ESMN1; SMN2LMNA
SCHEMBL7589137 0.87 KDM4E (0.50) CYP19A1KDM4ESMN1; SMN2LMNA
SCHEMBL2788882 0.87 KDM4E (0.50) CYP19A1KDM4ESMN1; SMN2LMNA
SCHEMBL4908140 0.84 CYP3A4 (0.42) CYP3A4CYP19A1KDM4ESMN1; SMN2LMNA
SCHEMBL17847834 0.84 CYP17A1 (0.44) CYP3A4CYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL31040269 0.82 SMN1; SMN2 (0.41) CYP19A1KDM4ESMN1; SMN2LMNAPRKDC
SCHEMBL6920072 0.82 MAPK1 (0.45) CYP19A1KDM4ESLC6A2SLC6A4SLC6A3
SCHEMBL4899497 0.82 HTT (0.45) SMN1; SMN2LMNACYP2C19PRKDCKCNH2
SCHEMBL4910223 0.80 ALDH1A1 (0.50) CYP17A1CYP19A1CYP2C19BRD4GAA
SCHEMBL5617833 0.76 L3MBTL1 (0.58) CYP3A4CYP19A1KDM4ELTA4HSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2019-01-29 US disclosed
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2019-01-29 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
WO-2016096126-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, OPRM1, SIGMAR1 CYP3A4 399/4885CYP11B1 1510/4885CYP11B2 1357/4885
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain OPRD1, OPRM1, SIGMAR1 CYP3A4 399/4885CYP11B1 1510/4885CYP11B2 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.